BidaskClub downgraded shares of Pacira Biosciences (NASDAQ:PCRX) from a sell rating to a strong sell rating in a research report released on Saturday, BidAskClub reports.

A number of other equities research analysts have also recently issued reports on the company. Stifel Nicolaus set a $42.00 price objective on Pacira Biosciences and gave the stock a hold rating in a research note on Friday, August 9th. BMO Capital Markets cut their target price on shares of Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research note on Friday, August 9th. Barclays initiated coverage on Pacira Biosciences in a report on Tuesday, June 11th. They set an overweight rating and a $52.00 price target for the company. Wedbush set a $85.00 price target on Pacira Biosciences and gave the stock a buy rating in a research report on Friday, June 28th. Finally, Zacks Investment Research upgraded Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price objective on the stock in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the company’s stock. Pacira Biosciences currently has an average rating of Hold and a consensus price target of $54.13.

Shares of PCRX stock opened at $36.74 on Friday. Pacira Biosciences has a 12 month low of $34.64 and a 12 month high of $55.00. The company’s fifty day simple moving average is $39.72 and its 200-day simple moving average is $41.03. The firm has a market cap of $1.49 billion, a PE ratio of 126.69, a P/E/G ratio of 1.61 and a beta of 1.13. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99.

Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, August 8th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.27. The business had revenue of $102.60 million during the quarter, compared to the consensus estimate of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.24 earnings per share. On average, equities analysts predict that Pacira Biosciences will post 0.66 earnings per share for the current fiscal year.

In related news, CEO David M. Stack sold 13,115 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $42.88, for a total transaction of $562,371.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Kristen Marie Williams sold 6,252 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,216 shares of company stock valued at $1,312,301. Corporate insiders own 5.80% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Frontier Capital Management Co. LLC bought a new stake in shares of Pacira Biosciences during the 1st quarter valued at $52,509,000. D. E. Shaw & Co. Inc. lifted its position in Pacira Biosciences by 32.5% during the second quarter. D. E. Shaw & Co. Inc. now owns 1,248,573 shares of the company’s stock worth $54,301,000 after purchasing an additional 306,129 shares during the period. Stephens Investment Management Group LLC lifted its position in Pacira Biosciences by 0.9% during the second quarter. Stephens Investment Management Group LLC now owns 1,210,605 shares of the company’s stock worth $52,649,000 after purchasing an additional 10,868 shares during the period. Point72 Asset Management L.P. grew its stake in Pacira Biosciences by 83.8% during the second quarter. Point72 Asset Management L.P. now owns 1,164,641 shares of the company’s stock worth $50,650,000 after buying an additional 531,059 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Pacira Biosciences by 2.7% during the second quarter. Renaissance Technologies LLC now owns 1,092,200 shares of the company’s stock worth $47,500,000 after buying an additional 28,600 shares in the last quarter.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

See Also: How to interpret Moving Average Convergence Divergence (MACD)

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.